Japan Pharmas Seek Advantages In High Hay Fever Season
This article was originally published in PharmAsia News
Japanese drug makers seek to expand their lines of hay fever drugs to take advantage of a heavy season for the ailment by offering year-round offshoots. Some firms are emphasizing protection against house dust and pollen from a Japanese cypress while others seek to make over-the-counter versions of prescription drugs. The pollen count in Japan this spring is projected to be as much as 200 percent higher than last year in parts of the country. (Click here for more - a subscription may be required
You may also be interested in...
A more conservative US Supreme Court may mean a less authoritative FDA, and drug pricing won’t get as much attention in the presidential campaign, which is a good thing.
The US HHS played defense on 20 September, pushing back on suggestions that secretary Alex Azar’s recent move to exert control over regulations by signing off on them was a power play aimed at the FDA. Meanwhile, former agency head Scott Gottlieb says it’s “the wrong move at the wrong time.”
With list due 4 November, there may not be time for public comment. Meanwhile, where will biopharma find fill/finish capacity?